Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufacturing capability, including existing facility and all related personnel.

Collaboration combines Quell's pioneering autologous multi-modular Treg cell therapy platform and Cellistic™'s expertise in iPSC cell therapy platform development and scale-up

Ncardia launches Cellistic™, the only iPSC-based cell therapy process development & manufacturing partner purpose-built to make large-scale allogeneic cell therapy production a reality today.

Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it has secured more than $60 million in capital through a strategic partnership with Kiniciti, a U.S.-based investment platform focused on strengthening the cell and gene therapy ecosystem worldwide.

Kiniciti, a Welsh, Carson, Anderson & Stowe (“WCAS”) platform company that invests in cell and gene therapy innovation, announced today that Biospring Partners has joined WCAS as an investor in Kiniciti. Dr. Michelle Dipp, Biospring’s Managing Partner, will serve on Kiniciti’s Board of Directors.

Kiniciti, a Welsh, Carson, Anderson & Stowe (“WCAS”) platform company that invests in non-therapeutic companies supporting Cell and Gene Therapy innovation, announced the formation of an advisory board and appointment of two inaugural members: Denis Bedoret, PhD, chief executive officer of Imcyse, and Andrew Knudten, chief operating officer of Jaguar Gene Therapy.

Welsh, Carson, Anderson & Stowe (“WCAS”), a leading private equity firm focused exclusively on the healthcare and technology industries, announced today that it is committing up to $250 million to a strategic partnership with Kiniciti, a newly-formed platform. Kiniciti will invest in non-therapeutic companies supporting cell and gene therapy (“CGT”) innovation which have the potential to transform the cell and gene therapy ecosystem and deliver the promise of CGT to impact patients’ lives.